Repligen Co. (NASDAQ:RGEN) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 30.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 120,991 shares of the biotechnology company’s stock after selling 52,435 shares during the quarter. Principal Financial Group Inc. owned approximately 0.22% of Repligen worth $18,006,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of RGEN. Thrivent Financial for Lutherans grew its holdings in shares of Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after purchasing an additional 425,061 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after buying an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC increased its position in Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after buying an additional 199,322 shares during the period. Dimensional Fund Advisors LP lifted its stake in Repligen by 39.4% in the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after buying an additional 121,305 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Repligen by 14.4% in the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after buying an additional 71,274 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Down 5.3 %

Shares of Repligen stock opened at $142.43 on Friday. The business has a fifty day simple moving average of $141.59 and a 200-day simple moving average of $144.78. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The firm has a market cap of $7.98 billion, a price-to-earnings ratio of -384.94, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The firm had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the previous year, the business earned $0.23 earnings per share. Repligen’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, equities analysts forecast that Repligen Co. will post 1.45 EPS for the current fiscal year.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on RGEN shares. JPMorgan Chase & Co. increased their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Wolfe Research initiated coverage on Repligen in a research report on Thursday. They set a “peer perform” rating for the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Benchmark reaffirmed a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.